



Original Article



Association of Serum Asprosin with the Risk Assessment of Diabetic Retinopathy

Aneela Sarwer¹, Alina Atif², Sana Saeed³, Shahneela Perveen⁴, Aqsa Sabir¹ and Mehir Un Nisa Iqbal⁵

¹Department of Physiology, Al-Tibri Medical College, Isra University, Karachi, Pakistan

²Department of Physiology, Jinnah Medical and Dental College, Karachi, Pakistan

³Department of Physiology, Dow University of Health Sciences, Karachi, Pakistan

⁴Department of Physiology, Dr Ishrat Ul Ebad Khan Institute of Oral Health Sciences, Dow University of Health Sciences, Karachi, Pakistan

⁵Department of Physiology, University of Karachi, Karachi, Pakistan

ARTICLE INFO

Keywords:

Diabetic Retinopathy, Asprosin, Diabetes, Serum

How to Cite:

Sarwer, A., Atif, A., Saeed, S., Perveen, S., Sabir, A., & Iqbal, M. U. N. (2025). Association of Serum Asprosin with the Risk Assessment of Diabetic Retinopathy: Association of Serum Asprosin with the Risk Assessment. *Pakistan Journal of Health Sciences*, 6(7), 276-280. <https://doi.org/10.54393/pjhs.v6i7.3116>

***Corresponding Author:**

Ubedullah Bahalkani
 Department of Pediatrics, Khairpur Medical College,
 Khairpur Mir's, Pakistan
ubedullahdr@yahoo.com

Received Date: 30th April, 2025

Revised Date: 21st July, 2025

Acceptance Date: 27th July, 2025

Published Date: 31st July, 2025

ABSTRACT

Diabetic retinopathy (DR) is a microvascular complication of uncontrolled diabetes, resulting from impaired retinal blood circulation. Asprosin, a recently identified adipokine, exacerbates this condition by inducing inflammatory cytokines that enhance retinal inflammation and vascular permeability. **Objectives:** To investigate the association of serum Asprosin levels with the progression of diabetic retinopathy and its potential role as a biomarker for early diagnosis and disease monitoring. **Methods:** This cross-sectional analytical study was conducted from January to December 2023, involving 255 participants divided into three groups: diabetics with no retinopathy, diabetics with retinopathy, and non-diabetic controls (85 each). Serum Asprosin, fasting glucose, insulin, lipid profiles, and other relevant clinical features were evaluated. Statistical analyses were conducted using SPSS version 26, including One-Way ANOVA, the Bonferroni test, and Pearson's correlation. **Results:** The group with retinopathy showed the highest levels of Asprosin, insulin, fasting glucose, triglycerides, and LDL, while HDL was lowest in this group. The diabetic group showed intermediate levels, and controls showed the lowest levels across these variables. A strong positive correlation was observed between Asprosin and insulin resistance indicators such as HOMA-IR. **Conclusions:** Elevated serum Asprosin correlates with the presence and severity of diabetic retinopathy and aligns with dysregulated lipid and glycemic profiles. These findings support the potential of Asprosin as an early biomarker for DR risk and progression. Future longitudinal studies are necessary to determine its causal role and clinical applicability in diabetes-related retinal complications.

INTRODUCTION

Diabetes mellitus (DM) is one of the biggest health challenges we face today, marked by issues with insulin production or function that result in high blood sugar levels [1]. To date, most attention has been placed on Type 2 DM because of its increasing incidence and associated complications. If not controlled, high blood sugar can cause serious issues, including damage to the eyes, kidneys, and harm to the blood vessels and nerves [2]. One such major long-range complication is Diabetic Retinopathy (DR), which arises from blood flow inadequacy to the retina and can eventually result in impaired vision and

even blindness [3]. DR is the leading cause of global blindness, and the good news is that it is largely preventable with early detection and treatment [4]. It is important to manage this condition to enable blood sugar levels, hypertension, and cholesterol to stay under control [5]. While blood sugar levels remain elevated, it creates advanced glycation end products (AGEs) that damage the tiny blood vessels in the retina and lead to leaks, vitreous hemorrhage, and retinal detachment [6]. The diabetes-associated increased permeability of blood vessels, inflammation, endothelial cell damage, and high



concentration of inflammatory cytokines are responsible for DR in its advanced stages [7]. Asprosin, a peptide hormone discovered in 2016, has a significant role in regulating blood glucose through interactions with OLF734 receptors in various organs [8]. It is negatively associated with HOMA-B and positively with HOMA-IR, indicating its link with insulin resistance [9]. When Asprosin is high, as in diabetes, it leads to insulin resistance and persistent hyperglycemia, which worsens DR [10]. By increasing oxidative stress and inflammation in the retinal tissue, asprosin makes the situation worse by hastening the destruction to the retina's blood vessels and cells. Inflammatory cytokines are produced in response to it, and this can exacerbate retinal inflammation and increase vascular permeability [11]. As a result, the blood-retinal barrier breaks down, allowing fluids and blood to seep into the retina and resulting in macular edema [9]. Additionally, asprosin affects angiogenesis by modifying the expression of VEGF (vascular endothelial growth factor), which results in aberrant and delicate angiogenesis. These vessels are prone to bleeding, contributing to retinal hemorrhages and further visual impairment. Through enhanced oxidative stress and inflammation in the retinal tissues, Asprosin accelerates the devastation of retinal blood vessels and cells, weakening the blood retinal barrier. This leads to macular edema and eventual vision loss [10]. Given these multifaceted roles, asprosin represents a potential therapeutic target for treating diabetic retinopathy. Interventions aimed at reducing asprosin levels or blocking its activity may offer new avenues for preventing or slowing the progression of this vision-threatening condition [12]. Despite significant advances in the understanding of diabetic retinopathy (DR), identifying reliable biomarkers for its early detection and progression remains a major challenge. Recent studies have highlighted the metabolic hormone Asprosin as a potential regulator of glucose metabolism and insulin resistance. However, limited research has explored its association with retinal microvascular complications, particularly diabetic retinopathy. Furthermore, evidence regarding the relationship between serum Asprosin levels and DR risk in diverse populations remains scarce, creating a need for further investigation. This study aimed to investigate the connection between Asprosin levels and diabetic retinopathy (DR) in a varied group of participants.

METHODS

This cross-sectional analytical study was conducted in the Outpatient Departments of Diabetes and Ophthalmology between January and December 2023, after obtaining ethical approval from the IRB of Al-Ibrahim Eye Hospital, Isra Postgraduate Institute of Ophthalmology, Karachi, Pakistan (Letter No. REC/IPIO/2023/067). A total of 255

participants were enrolled and divided equally into three groups of 85 each: diabetics with diabetic retinopathy (DR), diabetics without DR, and healthy individuals. Patients with DR were diagnosed through fundus examination, following international clinical retinopathy guidelines. A purposive sampling method was employed with specific inclusion and exclusion criteria. Individuals with non-diabetic eye diseases, active inflammation, chronic infections, steroid use, or conditions affecting glucose metabolism and obesity were excluded. The minimum sample size was calculated using the online software OpenEpi, referencing a previous study ("Frequency of Diabetic Retinopathy in Karachi, Pakistan: A Hospital-Based Study," 2015). The prevalence of DR was taken as 6.5%, with a 95% confidence level, 5% margin of error, population size (N) of 100,000, and a design effect (DEFF) of 1. The formula applied was:

$$n = \frac{DEFF \times N \times p(1-p)}{\left(\frac{d^2}{Z_{1-\alpha/2}^2} \times (N-1) \right) + p(1-p)}$$

where $Z_{1-\alpha/2} = 1.96$, $Z_{[1-\alpha/2]} = 1.96$. This yielded a minimum required sample size of 93. However, we recruited 255 participants to improve statistical power and subgroup analyses. All participants provided informed consent in their native language. A self-designed, pre-tested questionnaire was used to collect demographic details, lifestyle and dietary habits, medical history, and current or past treatments. Anthropometric measurements (including BMI) were recorded, along with blood pressure, pulse, respiratory rate, and pulse pressure. A fasting venous blood sample (5 ml) was collected, centrifuged, and the serum was stored at -20°C for analysis. Fasting blood glucose was measured using sodium fluoride vacutainers, while serum Asprosin and insulin levels were quantified using a human ELISA kit (Cat. No. E4095, sensitivity: 0.23 ng/ml; [Manufacturer, Country]). Data were analyzed using SPSS version 26.0. For normally distributed continuous data, one-way ANOVA with a Bonferroni post hoc test was applied. Pearson's correlation was used to evaluate relationships between anthropometric and biochemical parameters, with a particular focus on serum Asprosin levels.

RESULTS

Study results demonstrate significant differences in demographic measurements (age, weight, height, BMI, systolic and diastolic blood pressure, and pulse rate) across the control, diabetic, and retinopathy groups, with p-values around or close to <0.001 . These variations indicate distinct physiological profiles among the groups (Table 1).

Table 1: Demographic and General Physical Parameter Analysis of the Study Groups

Variables	Controls (N=85) Mean ± SD	Diabetics (N=85) Mean ± SD	Retinopathy (N=85) Mean ± SD	F-Value	p-Value
Age	40.37 ± 9.599	50.98 ± 7.543	51.84 ± 6.469	54.155	<0.001
Weight (kg)	67.65 ± 8.35	65.36 ± 8.76	67.64 ± 7.54	2.164	0.117
Height (cm)	167.35 ± 7.68	162.64 ± 10.27	165.64 ± 8.36	6.148	0.002
BMI (kg/m ²)	24.38 ± 2.62	25.05 ± 3.35	25.07 ± 2.72	1.513	0.222
Systolic BP (mmHg)	118.51 ± 7.67	117.88 ± 7.57	116.00 ± 8.27	2.350	0.097
Diastolic BP (mmHg)	75.10 ± 8.61	76.59 ± 6.82	74.47 ± 6.86	1.802	0.167
Pulse rate (b/min)	74.07 ± 3.73	75.29 ± 4.17	77.96 ± 5.33	16.828	<0.001
Pulse Pressure	42.74 ± 5.98	41.18 ± 3.75	41.82 ± 6.76	1.632	0.198
R/R (Breaths/min)	15.57 ± 2.17	16.06 ± 2.16	14.62 ± 2.16	9.651	<0.001

The analysis of biochemical markers demonstrated significant disparities among the groups. Lipid parameters (cholesterol, triglycerides, HDL, LDL, and VLDL), fasting blood sugar (FBS), fasting insulin, HOMA-IR, and serum Asprosin all had highly significant p-values of <0.001, suggesting notable differences in metabolic and lipid profiles between the groups. The biochemical analysis of serum Asprosin revealed significant differences between groups. Specifically, the Retinopathy group exhibited the highest Asprosin levels, followed by the Diabetic and Control groups (Table 2).

Table 2: Biochemical Analysis of the Study Groups

Variables	Controls (N=85) Mean ± SD	Diabetics (N=85) Mean ± SD	Retinopathy (N=85) Mean ± SD	F-Value	p-Value
Cholesterol	152.69 ± 9.59	177.32 ± 8.62	331.38 ± 4.35	85.90	<0.001
Triglycerides	157.25 ± 6.38	219.25 ± 1.27	449.10 ± 5.63	67.24	<0.001
HDL	63.42 ± 5.57	56.74 ± 18.33	33.79 ± 8.06	95.39	<0.001
LDL	70.19 ± 9.46	67.40 ± 34.77	207.89 ± 2.43	49.78	<0.001
VLDL	31.45 ± 13.28	43.85 ± 28.85	89.82 ± 50.53	67.24	<0.001
FBS	94.75 ± 7.10	124.34 ± 37.37	146.85 ± 7.90	48.48	<0.001
Fasting Insulin	0.71 ± 2.48	2.39 ± 9.29	7.02 ± 3.85	8.61	<0.001
HOMA-IR	0.17 ± 0.58	68 ± 2.69	2.70 ± 5.80	11.01	<0.001
Asprosin	19.99 ± 7.83	26.79 ± 8.67	47.30 ± 11.59	189.423	<0.001

Asprosin positively correlates with age, hypertension, diabetes status, and pulse rate, indicating higher levels in older individuals. A negative correlation with gender

suggests lower levels in males. Weak negative correlations were found with systolic and diastolic blood pressure, but no significant correlation was observed with weight, height, BMI, or pulse pressure. These findings suggest Asprosin's potential as a biomarker for age-related changes, hypertension, and diabetes (Table 3).

Table 3: Correlation of Asprosin with Demographic and General Physical Parameters

Variables	Pearson Correlation	p-Value
Age (in years)	0.317**	<0.001
Gender	-0.178**	0.004
Hypertension	0.222**	<0.001
Diabetes	0.581**	<0.001
Weight (kg)	0.006	0.930
Height (cm)	-0.019	0.759
BMI (kg/m ²)	0.036	0.570
Systolic BP (mmHg)	-0.128*	0.041
Diastolic BP (mmHg)	-0.136*	0.030
Pulse rate (beats/min)	0.279**	<0.001
Pulse pressure	-0.005	0.935
R/R (breaths/min)	-0.187**	0.003

**Correlation is significant at the 0.01 level (2-tailed). At a 95% confidence interval

*Correlation is significant at the 0.05 level (2-tailed). At a 95% confidence interval

BMI body mass index, blood pressure/R respiratory rate

The study found significant positive linear correlations between Asprosin and FBS, fasting insulin, HOMA-IR, cholesterol, triglycerides, LDL, and VLDL, indicating that higher Asprosin levels were associated with adverse metabolic profiles. In contrast, a significant negative correlation was observed between Asprosin and HDL, suggesting that elevated Asprosin levels may be linked to lower HDL levels, which are critical for cardiovascular and overall health (Table 4).

Table 4: Correlation of Asprosin with Biochemical Factors

Variables	Pearson Correlation (r)	p-Value
Cholesterol	0.481**	<0.001
Triglycerides	0.431**	<0.001
HDL	-0.586**	<0.001
LDL	0.483**	<0.001
VLDL	0.431**	<0.001
FBS	0.501**	<0.001
Fasting Insulin	0.315**	<0.001
HOMA-IR	0.321**	<0.001

**Correlation is significant at the 0.01 level (2-tailed)

*Correlation is significant at the 0.05 level (2-tailed).

HDL high high-density lipoprotein; LDL low density lipoprotein; VLDL: very low-density lipoprotein; FBS: fasting blood sugar; HOMA-IR: homeostatic assessment model of insulin resistance

DISCUSSION

When we compared the demographic and physical parameters, we noticed some significant differences among the groups we studied. The participants in the retinopathy group were older than those in the diabetic group, while the control group was notably younger than both. Ongoing hyperglycemia gradually weakens the retinal blood vessels, which play a role in diabetic retinopathy (DR), a condition that tends to be more severe in older individuals [13]. Previous research has also found a positive link between the prevalence of DR and the duration of diabetes, likely due to age-related changes in the retina that diminish macular blood flow and increase metabolic alterations. In comparison to the control group, both the diabetic and retinopathy groups showed higher BMI values, highlighting the connection between obesity, diabetes, and related complications. Earlier studies have similarly confirmed that a higher BMI is associated with diabetes, as excess body fat disrupts insulin metabolism through hormones and inflammatory markers, leading to insulin resistance and increased blood sugar levels [14]. The retinopathy group exhibited significantly altered lipid profiles compared to the diabetic group, while the control group maintained normal levels. Dyslipidemia can result in cholesterol buildup in the retina, which may lead to crystallization and contribute to DR, a finding that aligns with previous studies [15]. Current research revealed that the retinopathy group had higher levels of fasting blood sugar (FBS), fasting insulin (FI), and HOMA-IR compared to the other groups. In contrast, these parameters were within the normal range for the control group. Long-term high blood sugar can lead to various complications, including tissue inflammation, fluid imbalances, and damage to the retinal blood vessels, which aligns with findings from previous studies [16]. In the current study, serum Asprosin levels differed among the groups, peaking in the retinopathy group, followed by the diabetic group, and being the lowest in the control group. This peptide hormone is known to play a role in insulin sensitivity, appetite control, and energy balance, as highlighted in earlier research [17]. Interestingly, serum Asprosin levels tend to rise with age and prolonged diabetes, hinting at a link to metabolic issues like obesity and insulin resistance, which are more prevalent in older individuals. We observed some gender differences too, with females showing higher serum Asprosin levels than males, a finding that previous studies have also supported. This difference could be attributed to hormonal variations, body composition, and metabolic needs [18]. For instance, estrogen might boost Asprosin production, while testosterone could have the opposite effect, explaining these discrepancies. The severity of diabetes also plays a role in serum Asprosin

levels, with those experiencing poorly controlled diabetes showing higher levels compared to those with better control. Elevated Asprosin levels were positively correlated with fasting insulin, fasting blood glucose, HOMA-IR, LDL, and triglycerides, underscoring its involvement in disrupted glucose metabolism and diabetic complications [19]. Conversely, we found a negative correlation between Asprosin and HDL. Previous studies have further reinforced these connections, indicating that uncontrolled blood sugar levels can lead to complications like diabetic retinopathy [20].

The cross-sectional study design is one of the limitations of the study, as the patient sample was taken only once in the study. It was carried out at a single center setting, which may limit its generalizability to other clinical settings. Several factors, like the stage and severity of diabetic retinopathy (DR), duration of illness, medication usage, or patient compliance, were not accounted for in this study, which may limit the findings. Future studies should be conducted in compliance with the above limitations may produce profound effects on findings.

CONCLUSIONS

Higher levels of Asprosin might act as both diagnostic and prognostic indicators for DR, highlighting metabolic stress and inadequate glycemic control. This biomarker could be instrumental in pinpointing patients who are at a greater risk for DR, potentially allowing for timely interventions to prevent or slow down its progression. Asprosin shows great potential as a means for early detection and focused treatment of complications related to diabetic retinopathy. As it was a cross-sectional study, future longitudinal studies are needed to establish causality and determine its clinical utility.

Authors' Contribution

Conceptualization: AA, MUNI
 Methodology: AS, MUNI
 Formal analysis: AA, MUNI
 Writing and Drafting: SS, SP, AS
 Review and Editing: SS, SP, AS, MUNI

All authors approved the final manuscript and take responsibility for the integrity of the work

Conflicts of Interest

All the authors declare no conflict of interest.

Source of Funding

The author received no financial support for the research, authorship and/or publication of this article.

REFERENCES

- [1] Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 Diabetes. *The Lancet*. 2022 Nov; 400(10365): 1803-20. doi: 10.1016/S0140-6736(22)01655-5.

- [2] Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden Through 2045: Systematic Review and Meta-Analysis. *Ophthalmology*. 2021 Nov; 128(11): 1580-91. doi: 10.1016/j.ophtha.2021.04.027.
- [3] Kim MS, Park SJ, Joo K, Woo SJ. Trends and Barriers in Diabetic Retinopathy Screening: Korea National Health and Nutritional Examination Survey 2016-2021. *Journal of Korean Medical Science*. 2024 Jul; 39(27): e203. doi: 10.3346/jkms.2024.39.e203.
- [4] Antonetti DA, Silva PS, Stitt AW. Current Understanding of the Molecular and Cellular Pathology of Diabetic Retinopathy. *Nature Reviews Endocrinology*. 2021 Apr; 17(4): 195-206. doi: 10.1038/s41574-020-00451-4.
- [5] Ansari P, Tabasumma N, Snigdha NN, Siam NH, Panduru RV, Azam S, et al. Diabetic Retinopathy: An Overview on Mechanisms, Pathophysiology, and Pharmacotherapy. *Diabetology*. 2022 Feb; 3(1): 159-75. doi: 10.3390/diabetology3010011.
- [6] Rohilla M, Bansal S, Garg A, Dhiman S, Dhankhar S, Saini M, et al. Discussing Pathologic Mechanisms of Diabetic Retinopathy and Therapeutic Potentials of Curcumin and β -Glucogallin in the Management of Diabetic Retinopathy. *Biomedicine and Pharmacotherapy*. 2023 Dec; 169: 115881. doi: 10.1016/j.biopha.2023.115881.
- [7] Tang H, Luo N, Zhang X, Huang J, Yang Q, Lin H, et al. Association Between Biological Aging and Diabetic Retinopathy. *Scientific Reports*. 2024 May; 14(1): 10123. doi: 10.1038/s41598-024-60913-x.
- [8] Romere C, Duerschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. *Cell*. 2016 Apr; 165(3): 566-79. doi: 10.1016/j.cell.2016.02.063.
- [9] Abed BA, Salman IN, Ghannawi LA. Review of Asprosin as a New Biomarker for the Diagnosis of Different Diseases. *Journal of Thi-Qar Science*. 2023; 10(2). doi: 10.32792/utq/utjsci/v10i2.1125.
- [10] Shabir K, Brown JE, Afzal I, Gharanei S, Weickert MO, Barber TM, et al. Asprosin, a Novel Pleiotropic Adipokine Implicated in Fasting and Obesity-Related Cardio-Metabolic Disease: Comprehensive Review of Preclinical and Clinical Evidence. *Cytokine and Growth Factor Reviews*. 2021 Aug; 60: 120-32. doi: 10.1016/j.cytogfr.2021.05.002.
- [11] Seo H, Park SJ, Song M. Diabetic Retinopathy: Mechanisms, Current Therapies, and Emerging Strategies. *Cells*. 2025 Mar; 14(5): 376. doi: 10.3390/cells14050376.
- [12] Farrag M, Ait Eldjoudi D, González-Rodríguez M, Cordero-Barreal A, Ruiz-Fernandez C, Capuozzo M, et al. Asprosin in Health and Disease: A New Glucose Sensor With Central and Peripheral Metabolic Effects. *Frontiers in Endocrinology*. 2023 Jan; 13: 1101091. doi: 10.3389/fendo.2022.1101091.
- [13] Li Y, Tian J, Hou T, Gu K, Yan Q, Sun S, et al. Association Between Age at Diabetes Diagnosis and Subsequent Incidence of Cancer: A Longitudinal Population-Based Cohort. *Diabetes Care*. 2024 Mar; 47(3): 353-61. doi: 10.2337/dc23-0386.
- [14] Chandrasekaran P, Weiskirchen R. Diabetes Mellitus and Heart Disease. *Metabolism Target Organ Damage*. 2024 Apr; 4: 18. doi: 10.20517/mtod.2024.15.
- [15] Li Y, Mitchell W, Elze T, Zebardast N. Association Between Diabetes, Diabetic Retinopathy, and Glaucoma. *Current Diabetes Reports*. 2021 Oct; 21(10): 38. doi: 10.1007/s11892-021-01404-5.
- [16] Poshtchaman F, Dehnavi A, Poshtchaman Z, Birjandi B. HbA1C, Proliferative and Non-Proliferative Retinopathy in Diabetic Patients. *Medicina Clinica Practica*. 2023 Jul; 6(3): 100371. doi: 10.1016/j.mcsp.2023.100371.
- [17] Liang Y, Zhang X, Mei W, Li Y, Du Z, Wang Y, et al. Predicting Vision-Threatening Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus: Systematic Review, Meta-Analysis, and Prospective Validation Study. *Journal of Global Health*. 2024 Oct; 14: 04192. doi: 10.7189/jogh.14.04192.
- [18] Kropp M, Golubnitschaja O, Mazurakova A, Koklesova L, Sargheini N, Vo TT, et al. Diabetic Retinopathy as the Leading Cause of Blindness and Early Predictor of Cascading Complications-Risks and Mitigation. *Epma Journal*. 2023 Mar; 14(1): 21-42. doi: 10.1007/s13167-023-00314-8.
- [19] Cui T, Lin D, Yu S, Zhao X, Lin Z, Zhao L, et al. Deep Learning Performance of Ultra-Widefield Fundus Imaging for Screening Retinal Lesions in Rural Locales. *Journal of the American Medical Association Ophthalmology*. 2023 Nov; 141(11): 1045-51. doi: 10.1001/jamaophthalmol.2023.4650.
- [20] Ma L, Wang Z, Sun L, Li M, Wu Q, Liu M, et al. Association Analysis Between Serum Asprosin and Metabolic Characteristics, Complications in Type 2 Diabetic Patients With Different Durations. *Journal of Diabetes Investigation*. 2024 Dec; 15(12): 1781-7. doi: 10.1111/jdi.14313.